- HORIZON 2020
Two months after the first reports of the current outbreak of SARS-CoV-2, some of the most basic elements for risk assessment and targeted control measures are still unknown. CORESMA aism to directly address this need through unique mHealth, high resolution serolomics, and complementary approaches of mathematical modelling, artificial intelligence and implementation research in an ad-hoc implementation mode, including countries likely to be particularly affected or vulnerable.
For this purpose, the Multiplex Immunoassays Group at the NMI, in partnership with the HZI, will develop a multiplex serotest for SARS-CoV-2 to measure the seroprevalence of pre-existing cross and/or partial immunity in samples from the general population of Germany and Nepal. Any assay developed shall then undergo continuous development to track the ongoing evolution of SARS-CoV-2.
For further details please view https://www.coresma.eu/en/
- Helmholtz Centre for Infection Research (Germany), NMI, Rijksinstituut voor Volksgezondheid en Milieu (Netherlands), Swiss Tropical and Public Health Institute (Switzerland)